The Clorox Company (NYSE:CLX) Shares Sold by LRI Investments LLC

LRI Investments LLC trimmed its stake in The Clorox Company (NYSE:CLXFree Report) by 45.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 951 shares of the company’s stock after selling 800 shares during the quarter. LRI Investments LLC’s holdings in Clorox were worth $140,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Redwood Park Advisors LLC acquired a new position in Clorox in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new position in Clorox in the fourth quarter valued at $31,000. Wood Tarver Financial Group LLC acquired a new position in Clorox in the fourth quarter valued at $31,000. GKV Capital Management Co. Inc. acquired a new position in Clorox in the fourth quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Clorox in the fourth quarter valued at $33,000. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Price Performance

CLX stock opened at $127.50 on Tuesday. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a 1 year low of $117.35 and a 1 year high of $171.37. The firm has a market cap of $15.71 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 3.12 and a beta of 0.51. The stock has a 50-day simple moving average of $128.06 and a 200-day simple moving average of $142.04.

Clorox (NYSE:CLXGet Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter last year, the business posted $1.71 EPS. Clorox’s quarterly revenue was down 8.0% compared to the same quarter last year. On average, equities analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director owned 4,000 shares in the company, valued at $546,280. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.57% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Citigroup dropped their target price on Clorox from $165.00 to $150.00 and set a “neutral” rating for the company in a research note on Monday, April 14th. JPMorgan Chase & Co. dropped their target price on Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research note on Tuesday, May 6th. Barclays reduced their target price on Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a report on Wednesday, May 7th. Jefferies Financial Group dropped their price target on Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Finally, Morgan Stanley dropped their price target on Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Clorox currently has a consensus rating of “Hold” and an average target price of $148.92.

View Our Latest Analysis on CLX

Clorox Company Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

See Also

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLXFree Report).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.